David Brown
Psychiatry · Austin, TXNPI 1518086743
Payments from drug & device makers
Across 1,388 payments — averaging $11,355 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$4.2M
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$3.3M
- Teva Pharmaceuticals USA, Inc.$2.8M
- AbbVie$1.9M
- Vanda Pharmaceuticals Inc.$876K
- Hoffmann-la Roche Limited$774K
- plus $1.9M from 22 others
Across 16 payments — averaging $67.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$760
- Otsuka Pharmaceutical Development & Commercialization, Inc.$219
- AbbVie$95
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 15 | $4,202,907 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 62 | $3,335,280 |
| Teva Pharmaceuticals USA, Inc. | 459 | $2,765,479 |
| AbbVie(2 entities) | 113 | $1,859,133 |
| Vanda Pharmaceuticals Inc. | 30 | $875,600 |
| Hoffmann-la Roche Limited | 19 | $774,303 |
| Sunovion Pharmaceuticals Inc. | 322 | $584,551 |
| Alkermes, Inc. | 104 | $353,299 |
| E.r. Squibb & Sons, L.L.C. | 26 | $233,461 |
| Boehringer Ingelheim | 19 | $172,995 |
| Genentech, Inc. | 12 | $121,041 |
| Takeda Pharmaceuticals U.S.A., Inc. | 43 | $89,824 |
| Corcept Therapeutics | 6 | $88,877 |
| Sage Therapeutics, LLC | 14 | $82,310 |
| Tolmar, Inc. | 4 | $68,194 |
| Ocular Therapeutix, Inc. | 18 | $45,619 |
| Sumitomo Pharma America, Inc. | 17 | $31,491 |
| H. Lundbeck A S | 2 | $27,906 |
| Biogen | 3 | $13,792 |
| AstraZeneca | 1 | $13,446 |
| Bioxcel Therapeutics, Inc. | 2 | $12,227 |
| Boehringer Ingelheim RCV GmbH & Co KG | 19 | $7,266 |
| Otsuka America Pharmaceutical, Inc. | 46 | $776 |
| Johnson & Johnson | 9 | $186 |
| Neurocrine Biosciences, Inc. | 6 | $156 |
| Indivior Inc. | 7 | $152 |
| Lundbeck LLC | 5 | $71 |
| Merck | 5 | $42 |
How this compares
$15,760,385 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Austin
- Divyansu PatelAustin$2.8M
- Donald GarciaAustin$2.8M
- Arvinder Pal WaliaAustin$2.5M
- Charles SweetAustin$520K
- Charles NemeroffAustin$429K
- Scott BartleyDallas$42.7M
- Rajinder ShiwachDesoto$15.4M
- Darin OkudaDallas$14.7M
- Jason MensahBeaumont$10.3M
- Michael DowningDallas$7.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.